中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 10
Oct.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(10): 2044-2053

Association between the non-treatment threshold or upper limit of normal of alanine aminotransferase and liver pathological injury in patients with chronic hepatitis B virus infection and a persistently low level of alanine aminotransferase

DOI: 10.12449/JCH251014
  • 1.

    Liver Diseases Center，Ningbo Institute of Liver Diseases，Ningbo No. 2 Hospital，Ningbo，Zhejiang 315010，China

  • 2.

    Graduate School of Wenzhou Medical University，Wenzhou，Zhejiang 325035，China

  • 3.

    Graduate School of Ningbo University Health Science Center，Ningbo，Zhejiang 315211，China

  • 4.

    Graduate School of Shaoxing University School of Medicine，Shaoxing，Zhejiang 312000，China

Research funding:

Major Medical Scientific Research Foundation of National Health Commission-Zhejiang Province (WKJ-ZJ-2341);

Zhejiang Province Clinical Key Specialty Construction Project (2024023);

Ningbo Medical & Health Brand Discipline (PPXK2024-04);

Ningbo Public Welfare Research Foundation (2024S027)

More Information
  • Corresponding author: HU Airong， huairong@ucas.edu.cn （ORCID： 0000-0002-8176-2714）
  • Received Date: 2025-04-08
  • Accepted Date: 2025-06-19
  • Published Date: 2025-10-25
    Abstract
  •   Objective  To investigate the significance of different non-treatment thresholds or upper limits of normal （ULN） of alanine aminotransferase （ALT） in evaluating significant liver pathological injury in patients with chronic hepatitis B virus （HBV） infection， and to provide guidance for clinical diagnosis and treatment.  Methods  This study was conducted among 733 patients with chronic HBV infection who were hospitalized in Ningbo No. 2 Hospital from January 2015 to December 2023 and underwent liver biopsy and histopathological examination， and all patients had a persistent ALT level of ≤40 U/L and positive HBV DNA （>30 IU/mL）. According to the treatment threshold or ULN of ALT， the patients were divided into group 1 with 575 patients （≤35 U/L for male patients， ≤25 U/L for female patients）， group 2 with 430 patients （≤30 U/L for male patients， ≤19 U/L for female patients）， group 3 with 443 patients （≤27 U/L for male patients， ≤24 U/L for female patients）， group 4 with 446 patients （≤25 U/L）， group 5 with 158 patients （>35 U/L for male patients， >25 U/L for female patients）， and group 6 with 145 patients （>30 — ≤35 U/L for male patients， >19 — ≤25 U/L for female patients）. Groups 2， 5， and 6 were compared to analyze the severity of liver pathological injury in patients with different ALT levels and the constituent ratio of patients with significant liver pathological injury， and groups 1， 2， 3， and 4 were compared to investigate the value of different ULN or non-treatment thresholds of ALT in determining liver inflammation grade （G）， liver fibrosis stage （S）， and the treatment indication based on liver pathology. The independent-samples t test was used for comparison of normally distributed continuous data between two groups； a one-way analysis of variance was used for comparison between multiple groups， and the least significant difference t-test or the Tambane’s test was used for further comparison between two groups； the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between multiple groups and further comparison between two groups； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups； a Ridit analysis was used for comparison of ranked data. A multivariate Logistic regression analysis （forward stepwise） was performed with whether liver pathology met the treatment indication （≥G2 and/or ≥S2） as the dependent variable and related factors with a significant impact on the dependent variable （P <0.05） as the independent variable. The receiver operating characteristic （ROC） curve was plotted， and the area under the ROC curve （AUC）， as well as sensitivity， specificity， positive predictive value， negative predictive value， positive likelihood ratio， and negative likelihood ratio， was used to assess the diagnostic value of different non-treatment thresholds of ALT.  Results  Among the 733 patients， 259 （35.33%） had ≥G2 liver inflammation， 211 （28.79%） had ≥S2 liver fibrosis， and 306 （41.75%） had treatment indication （≥G2 and/or ≥S2）. There was a significant difference in liver inflammation grade （G0 — G4） between groups 2， 5， and 6 （χ2=22.869， P <0.001）， and there were also significant differences in the constituent ratios of patients with ≥G2 or ≥G3 liver inflammation between the three groups （χ2=21.742 and 14.921， P<0.001 and P=0.001）. There was a significant difference in liver fibrosis stage （S0 — S4） between groups 2， 5， and 6 （χ2=16.565， P<0.001）， and there were also significant differences in the constituent ratios of patients with ≥S2， ≥S3 or S4 liver fibrosis between the three groups （χ2=13.264， 13.050， and 6.260， P=0.001， 0.001， and 0.044）. There were significant differences between groups 2， 5， and 6 in the constituent ratios of patients with or without treatment indication based on liver pathology （χ2=20.728， P<0.001）. There were significant differences between groups 2， 5， and 6 in the constituent ratio of male patients （χ2=24.836， P<0.05）， age （F=5.710， P<0.05）， ALT （F=473.193， P<0.05）， aspartate aminotransferase （AST） （F=107.774， P<0.05）， ALT/AST ratio （F=40.167， P<0.05）， γ-glutamyl transpeptidase （GGT） （H=15.463， P<0.05）， aspartate aminotransferase-to-platelet ratio index （APRI） （H=63.024， P<0.05）， and LIF-5 （5 indicators for liver inflammation and fibrosis） （H=46.397， P<0.05）. In groups 1 — 4， compared with the patients without treatment indication， the patients with treatment indication had a significantly lower constituent ratio of patients with positive HBeAg， significantly lower levels of platelet count （PLT） and HBV DNA， and significantly higher age， ALT， AST， GGT， APRI， FIB-4， and LIF-5 （all P<0.05）. The Logistic regression analysis showed that age （odds ratio ［OR］=1.044， 95% confidence interval ［CI］： 1.025 — 1.063， P<0.001）， GGT （OR=1.022， 95%CI： 1.007 — 1.038， P=0.003）， and HBV DNA （OR=0.839， 95%CI： 0.765 — 0.919， P<0.001） were influencing factors for treatment indication based on liver pathology in group 1； HBeAg （OR=1.978， 95%CI： 1.269 — 3.082， P=0.003）， age （OR=1.048， 95%CI： 1.025 — 1.071， P<0.001）， GGT （OR=1.016， 95%CI： 1.001 — 1.031， P=0.041）， and PLT （OR=0.995， 95%CI： 0.991 — 1.000， P=0.049） were influencing factors in group 2； age （OR=1.040， 95%CI： 1.014 — 1.066， P=0.002）， ALT （OR=1.047， 95%CI： 1.005 — 1.092， P=0.029）， HBV DNA （OR=0.817， 95%CI： 0.736 — 0.907， P<0.001）， and LIF-5 （OR=7.382， 95%CI： 1.151 — 47.330， P=0.035） were influencing factors in group 3； age （OR=1.054， 95%CI： 1.031 — 1.077， P<0.001）， ALT （OR=1.061， 95%CI： 1.016 — 1.107， P=0.008）， and HBV DNA （OR=0.825， 95%CI： 0.743 — 0.917， P<0.001） were influencing factors in group 4. The diagnostic performance for identifying ≥G2 liver inflammation， ≥S2 liver fibrosis， and treatment indication in groups 1 — 4 had an AUC of >0.7； group 1 showed the lowest sensitivity （28.76%） and the highest specificity， positive predictive value， positive likelihood ratio， and negative likelihood ratio in judging treatment indication； group 2 had the highest sensitivity and negative predictive value and the lowest negative likelihood ratio； groups 3 and 4 had similar diagnostic indicators.  Conclusion  In patients with chronic HBV infection and a persistently low ALT level， the severity of liver histopathological injury and the constituent ratio of significant liver histopathological injury decrease with the reduction in ALT level. A higher non-treatment threshold or ULN of ALT can help to identify the patients requiring treatment （with a higher specificity）， while a lower non-treatment threshold or ULN of ALT can help to identify the patients who do not require treatment （with a higher sensitivity）.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    YOU H, WANG FS, LI TS, et al. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. J Clin Transl Hepatol, 2023, 11( 6): 1425- 1442. DOI: 10.14218/JCTH.2023.00320.
    [2]
    JENG WJ, PAPATHEODORIDIS GV, LOK ASF. Hepatitis B[J]. Lancet, 2023, 401( 10381): 1039- 1052. DOI: 10.1016/S0140-6736(22)01468-4.
    [3]
    DUSHEIKO G, AGARWAL K, MAINI MK. New approaches to chronic hepatitis B[J]. N Engl J Med, 2023, 388( 1): 55- 69. DOI: 10.1056/NEJ-Mra2211764.
    [4]
    ZHENG H, WANG Y, WANG FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: Evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51: 101193. DOI: 10.1016/j.lanwpc.2024.101193.
    [5]
    WONG RJ, KAUFMAN HW, NILES JK, et al. Simplifying treatment criteria in chronic hepatitis B: Reducing barriers to elimination[J]. Clin Infect Dis, 2023, 76( 3): e791- e800. DOI: 10.1093/cid/ciac385.
    [6]
    EASTERBROOK PJ, LUHMANN N, BAJIS S, et al. WHO 2024 hepatitis B guidelines: An opportunity to transform care[J]. Lancet Gastroenterol Hepatol, 2024, 9( 6): 493- 495. DOI: 10.1016/S2468-1253(24)00089-X.
    [7]
    MARTIN P, NGUYEN MH, DIETERICH DT, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update[J]. Clin Gastroenterol Hepatol, 2022, 20( 8): 1766- 1775. DOI: 10.1016/j.cgh.2021.07.036.
    [8]
    European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
    [9]
    HU AR, JIANG SW, SHI XJ, et al. Analysis on the normal threshold of alanine aminotransferase level based on liver pathology in patients with chronic hepatitis B[J]. J Hepatol, 2022, 77: S304. DOI: 10.1016/S0168-8278(22)00974-6.
    [10]
    KANG NL, WU LY, ZHENG Q, et al. Determining optimal ALT cut-off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther, 2024, 59( 5): 692- 704. DOI: 10.1111/apt.17862.
    [11]
    JIANG SW, HU AR, YAN HD, et al. Analysis on the judgment values of three non-invasive score systems(LIF-5, APRI and FIB-4) for treatment indication in chronic HBV infected patients with ALT less than two times of upper limits of normal[J]. Chin J Gen Pract, 2017, 15( 4): 558- 561. DOI: 10.16766/j.cnki.issn.1674-4152.2017.04.004.

    蒋素文, 胡爱荣, 颜华东, 等. 诊断模型对ALT正常值上限2倍以下慢性HBV感染者治疗指征的判断价值[J]. 中华全科医学, 2017, 15( 4): 558- 561. DOI: 10.16766/j.cnki.issn.1674-4152.2017.04.004.
    [12]
    Writing Group of the Xiangya Expert Consensus on Liver Needle Biopsy. Xiangya expert consensus on liver needle biopsy[J]. Chin J Gen Sur, 2021, 30( 1): 1- 8. DOI: 10.7659/j.issn.1005-6947.2021.01.001.

    肝脏穿刺活检湘雅专家共识编写组. 肝脏穿刺活检湘雅专家共识[J]. 中国普通外科杂志, 2021, 30( 1): 1- 8. DOI: 10.7659/j.issn.1005-6947.2021.01.001.
    [13]
    ZHOU ZN, PENG CH, WANG CF. Fast excel implementation of pairwise comparison between ridit analysis groups[J]. Chin J Hosp Stat, 2013, 20( 5): 345- 347. DOI: 10.3969/j.issn.1006-5253.2013.05.009.

    周治年, 彭长华, 王昌富. Ridit分析组间两两比较的Excel快速实现[J]. 中国医院统计, 2013, 20( 5): 345- 347. DOI: 10.3969/j.issn.1006-5253.2013.05.009.
    [14]
    DU YN, DU BY, FANG XY, et al. ALT flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: A cross-country cohort study[J]. Front Oncol, 2021, 10: 615203. DOI: 10.3389/fonc.2020.615203.
    [15]
    LIGUORI A, ZONCAPÈ M, CASAZZA G, et al. Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2025, 10( 4): 332- 349. DOI: 10.1016/S2468-1253(24)00437-0.
    [16]
    WONG GL, LEMOINE M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines[J]. J Hepatol, 2025, 82( 5): 918- 925. DOI: 10.1016/j.jhep.2024.12.004.
    [17]
    XUAN WY, JIANG SW, HU AR, et al. Liver histopathological changes in chronic HBV infection patients with alanine aminotransferase at different upper limits of normal value[J]. Chin J Clin Infect Dis, 2022, 15( 3): 193- 199. DOI: 10.3760/cma.j.issn.1674-2397.2022.03.005.

    宣王益, 蒋素文, 胡爱荣, 等. 丙氨酸转氨酶不同正常值上限的慢性HBV感染者肝组织病理改变分析[J]. 中华临床感染病杂志, 2022, 15( 3): 193- 199. DOI: 10.3760/cma.j.issn.1674-2397.2022.03.005.
    [18]
    ZHANG JY, CHEN SY, YOU H. Expanding initial anti-HBV therapy for chronic hepatitis B: Reducing the treatment threshold of alanine aminotransferase[J]. J Clin Hepatol, 2023, 39( 1): 27- 30. DOI: 10.3969/j.issn.1001-5256.2023.01.004.

    张佳怡, 陈姝延, 尤红. 扩大慢性乙型肝炎初始治疗: 降低ALT治疗阈值[J]. 临床肝胆病杂志, 2023, 39( 1): 27- 30. DOI: 10.3969/j.issn.1001-5256.2023.01.004.
    [19]
    XU CG, ZHAO Y, CHEN HZ, et al. Risk factors for significant histological changes in both HBeAg positive and negative treatment-naive chronic hepatitis B with persistently normal alanine aminotransferase level[J]. BMC Infect Dis, 2024, 24( 1): 1120. DOI: 10.1186/s12879-024-10015-w.
    [20]
    LIN MS, LIN HS, CHANG ML, et al. Alanine aminotransferase to aspartate aminotransferase ratio and hepatitis B virus on metabolic syndrome: A community-based study[J]. Front Endocrinol(Lausanne), 2022, 13: 922312. DOI: 10.3389/fendo.2022.922312.
    [21]
    LIU K, HUANG ZY, YANG SH, et al. The age, gamma-glutamyl transpeptidase and platelet index: A novel noninvasive model for predicting hepatocellular carcinoma in patients with hepatitis B virus-related liver cirrhosis[J]. J Hepatocell Carcinoma, 2022, 9: 1057- 1063. DOI: 10.2147/JHC.S386977.
    [22]
    JIANG SW, LIAN X, HU AR, et al. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication[J]. World J Gastroenterol, 2023, 29( 16): 2479- 2494. DOI: 10.3748/wjg.v29.i16.2479.
    [23]
    BONINO F, COLOMBATTO P, BRUNETTO MR. HBeAg-negative/anti-HBe-positive chronic hepatitis B: A 40-year-old history[J]. Viruses, 2022, 14( 8): 1691. DOI: 10.3390/v14081691.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(9)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (61) PDF downloads(7) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return